Lynx1 Capital Management LP and Weston Nichols File Schedule 13G/A for Cullinan Therapeutics, Inc.

Lynx1 Capital Management LP and Weston Nichols have filed an amendment to their Schedule 13G, reporting beneficial ownership of 14.5% of the common stock of Cullinan Therapeutics, Inc. The shares are held by Lynx1 Master Fund LP, which is managed by Lynx1 Capital Management LP. Weston Nichols is the sole member of the general partner of Lynx1 Capital Management LP. The filing indicates that the shares are not held for the purpose of influencing the control of the issuer. The total number of shares beneficially owned is 8,549,084, representing 14.5% of the outstanding shares as of July 31, 2025.